We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current IXC market cap is 5.86M. The company's latest EPS is AUD -0.1031 and P/E is -0.78.
| Year End June 29 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Total Revenue | 0 | 0 | 0 | 182k | 459k |
| Operating Income | -232k | -3.41M | -2.44M | -4.06M | -8.52M |
| Net Income | -232k | -3.36M | -2.28M | -3.95M | -7.75M |
| Year End June 29 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Total Assets | 12.37M | 26.42M | 32.74M | 29.49M | 22.8M |
| Total Liabilities | 935k | 2.02M | 659k | 1M | 1.57M |
| Total Equity | 11.44M | 24.4M | 32.08M | 28.48M | 21.23M |
| Year End June 29 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Operating | -230k | -1.6M | -1.68M | -3.38M | -6.87M |
| Investing | -8k | N/A | N/A | N/A | N/A |
| Financing | 12.41M | 15.73M | 8.09M | N/A | N/A |
| Market Cap | 5.86M |
| Price to Earnings Ratio | -0.78 |
| Price to Sales Ratio | 13.11 |
| Price to Cash Ratio | 0.27 |
| Price to Book Ratio | 0.28 |
| Dividend Yield | - |
| Shares Outstanding | 75.15M |
| Average Volume (1 week) | 27.1k |
| Average Volume (1 Month) | 54.48k |
| 52 Week Change | -82.27% |
| 52 Week High | 0.63 |
| 52 Week Low | 0.06 |
| Spread (Intraday) | 0.01 (11.76%) |
| Company Name | Invex Therapeutics Ltd |
| Address |
level 1, 38 rowland street perth, western australia 6008 |
| Website | https://www.invextherapeutics.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
